Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Moank in connection with the issuance of Additional Tier 1 Capital of SEK 150 million
Mandate

Vinge has advised Moank in connection with the issuance of Additional Tier 1 Capital of SEK 150 million

July 12, 2022 Banking and Finance

Vinge has advised the fintech company Credit Opportunity One AB (publ) (u.n.c.t. Moank Fintech Group AB (publ)) (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 150 million to optimise its capital structure.

The issuance is in the form of a debt instrument with automatic write-down of its nominal amount if the common equity tier 1 capital ratio of the Company falls below a certain level. The instruments will be listed on Nasdaq First North Bond Market.

 

Vinge’s team consisted of Albert Wållgren, Arvid Weimers and Felix Möller.

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026